504 related articles for article (PubMed ID: 33942128)
1. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
[TBL] [Abstract][Full Text] [Related]
2. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Hoy SM
Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre P; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DiPersio J; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Wong S; Lustgarten S; Rivera VM; Clackson T; Turner CD; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes T; Goldman JM; Shah NP; Kantarjian H;
N Engl J Med; 2013 Nov; 369(19):1783-96. PubMed ID: 24180494
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Cortes JE; Kantarjian H; Shah NP; Bixby D; Mauro MJ; Flinn I; O'Hare T; Hu S; Narasimhan NI; Rivera VM; Clackson T; Turner CD; Haluska FG; Druker BJ; Deininger MW; Talpaz M
N Engl J Med; 2012 Nov; 367(22):2075-88. PubMed ID: 23190221
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
8. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
[TBL] [Abstract][Full Text] [Related]
9. Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.
Shacham-Abulafia A; Raanani P; Lavie D; Volchek Y; Ram R; Helman I; Shargian L; Gourevitch A; Chubar E; Ratzon R; Rozovski U
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e295-e301. PubMed ID: 29773429
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre PD; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Lustgarten S; Rivera VM; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes TP; Shah NP; Kantarjian HM
Blood; 2018 Jul; 132(4):393-404. PubMed ID: 29567798
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
[TBL] [Abstract][Full Text] [Related]
16. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Cortes J; Apperley J; Lomaia E; Moiraghi B; Undurraga Sutton M; Pavlovsky C; Chuah C; Sacha T; Lipton JH; Schiffer CA; McCloskey J; Hochhaus A; Rousselot P; Rosti G; de Lavallade H; Turkina A; Rojas C; Arthur CK; Maness L; Talpaz M; Mauro M; Hall T; Lu V; Srivastava S; Deininger M
Blood; 2021 Nov; 138(21):2042-2050. PubMed ID: 34407543
[TBL] [Abstract][Full Text] [Related]
18. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
He JB; Zhang X; Guo ZW; Liu MM; Xu N; Huang F; Fan ZP; Xuan L; Deng L; Lin SH; Xu J; Sun J; Liu QF
Int J Cancer; 2020 Aug; 147(4):1071-1077. PubMed ID: 31785158
[TBL] [Abstract][Full Text] [Related]
20. Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
Kawano N; Kimura S; Miura M; Tochigi T; Nakaike T; Yamashita K; Mashiba K; Kikuchi I; Takahashi N
Int J Hematol; 2021 Oct; 114(4):509-516. PubMed ID: 34406581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]